On November 17, AKESO rose 3.28% intraday in Regular Trading, trading at HK$66.25, with turnover of HK$220 million.
The clearest catalyst for the rebound was the company’s disclosed share purchase by the trustee on November 16, totaling about 336,000 shares for roughly HK$21 million, funded by existing available cash, with the board stating this reflects confidence in business prospects and future outlook.
This followed sharp pressure after ivonescimab’s US biologics license application received a Complete Response Letter from the FDA. The company had said operations remain normal, while management moved quickly to communicate with investors. The buyback-related purchase appears to have provided near-term support for sentiment after the prior selloff tied to delayed US commercialization visibility.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments